Inhibition of EZH2 transactivation function sensitizes solid tumors to genotoxic stress
Abstract
We identified a group of DNA repair genes directly induced by EZH2 and repressed by EZH2 inhibitors. Expression of these genes predicts the response of wild-type EZH2-harboring solid tumors to EZH2 inhibitors. Most importantly, our findings lay the foundation for the development of a combination therapy that combines EZH2 inhibitors and DNA damaging agents or drugs that block DNA repair for the treatment of castration-resistant prostate cancer and other solid tumors.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jan 14, 2022
- Source ID
- 10.1073/pnas.2105898119
Entities
People
- Avery Feit
- Bárbara De La Peña Avalos
- Changmeng Cai
- Chen-hao Chen
- Eloise Dray
- Han Xu
- Henry Long
- James E. Bradner
- Ji Hoon Lee
- Jin Zhao
- Kexin Xu
- Kornélia Polyák
- Mei Yang
- Melissa Duarte
- Myles A. Brown
- Neel J. Shah
- Pengya Xue
- Philip W. Kantoff
- Roodolph S. Pierre
- Shaokun Shu
- Shenglin Mei
- Shuai Gao
- Steven P Balk
- Teng Fei
- Tengfei Xiao
- Wei Li
- Xiaole Shirley Liu
- Yiji Liao
- Zhao Zhang
- Zhijie Liu
Organizations
- American Association for Cancer Research
- Beth Israel Deaconess Medical Center
- Cancer Prevention and Research Institute of Texas
- Dana–Farber Cancer Institute
- Harvard Medical School
- Harvard University
- Max and Minnie Tomerlin Voelcker Fund
- National Cancer Institute
- National Human Genome Research Institute
- Prostate Cancer Foundation
- United States Department of Defense
- University of Massachusetts
- University of Texas Health Science Center at San Antonio